QR-koodi

Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status

Abstract Background/Aim For patients treated with osimertinib as first-line therapy, there have been no studies comparing both progression-free survival (PFS) and overall survival (OS) according to performance status (PS). Furthermore, no studies have examined differences in baseline genetic abnorma...

Täydet tiedot

Tallennettuna:
Päätekijät: Yoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, Daijiro Harada, Shun-ichi Isa, Keiichi Nakamura, Yasuyuki Mizumori, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Atsuhisa Tamura, Masahiko Ando, Yasuhiro Koh
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMC 2024-08-01
Sarja:BMC Pulmonary Medicine
Aiheet:
EGFR mutations
Osimertinib
Overall survival
Performance status
Progression-free survival
Linkit:https://doi.org/10.1186/s12890-024-03212-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia